Company: LENZ
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001628280-25-016815
Chunk: 9

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: POS AM
Chunk 9
---
 reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We may continue to be a smaller reporting company in any given year if either (i) the market value of our stock held by non-affiliates is less than $250 million as of June 30th in the most recently completed fiscal year, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million as of June 30th in the most recently completed fiscal year .

Unless expressly indicated or the context requires otherwise, the terms “LENZ,” “New LENZ,” the “Company,” the “Registrant,” “we,” “us” and “our” in this prospectus refer to LENZ Therapeutics, Inc., the parent entity formerly named Graphite Bio, Inc., after giving effect to the Merger, and as renamed LENZ Therapeutics, Inc., and where appropriate, our wholly-owned subsidiaries (including LENZ OpCo).

<div align='center'>2</div>

THE OFFERING

| Shares of Common Stock Offered Hereunder |     | An aggregate of 1,578,947 shares of Common Stock issued in the July 2024 PIPE Financing.                                                                                                                                                                        
 All aforementioned shares of Common Stock were initially registered in our Initial Registration Statement, and no new shares are being registered hereunder.                                                                                                    |
| Use of Proceeds                          |     | We will not receive any proceeds from the sale of our shares of common stock offered by the selling stockholder under this prospectus (the “Securities”). See the section titled “Use of Proceeds” appearing elsewhere in this prospectus for more information. |
| Common Stock Outstanding                 |     | 27,531,490 shares of Common Stock as of December 31, 2024.                                                                                                                                                                                                      |
| Risk Factors                             |     | See the section titled “Risk Factors” and other information included in this prospectus and the documents incorporated by reference for a discussion of factors that you should consider carefully before deciding to invest in our Common Stock.               |
| Nasdaq symbol                            |     | “LENZ” for our Common Stock.                                                                                                                                                                                                                                    |

The number of shares of Common Stock outstanding is based on 27,531,490 shares of Common Stock as of December 31, 2024 and excludes the following, in each case as of December 31,